All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?
Should pre-transplant MRD be used to guide treatment in AML?
Ossenkoppele begins by outlining emerging techniques in MRD, such as next-generation sequencing. He goes on to describe how risk category and MRD status can inform treatment decisions, such as for allogeneic stem cell transplant.
1st NCRI AML academy meeting | Advances in intensive chemotherapy for patients with AML
We spoke to Prof Gert Ossenkoppele at the 1st NCRI AML academy meeting about recent intensive chemotherapy advances for the treatment of patients with AML (acute...
The passing of Professor Francesco Lo Coco: the great pioneer of targeted therapy leaves the leukemia community
Professor Francesco Lo Coco passed away on March 3, 2019.
Subscribe to get the best content related to AML delivered to your inbox